UCB Biopharma SRL is conducting a phase three, multicenter, double-blind, randomized, placebo-controlled study to assess the efficacy, safety, and tolerability of Rozanolixizumab, a humanized monoclonal antibody that binds to the human FcRn receptor, in adults (18 years of age or older) with persistent or chronic primary ITP. The purpose is also to demonstrate the clinical efficacy of Rozanolixizumab as a maintenance therapy. Rozanolixizumab is administered through a subcutaneous injection. Participants must have tried, and responded to, at least one previous ITP-related medication. Participants must also be able to receive immunosuppressive treatments.
Republic of Moldova, Georgia
Recruiting on hold